← Back to Screener
Tempest Therapeutics, Inc. Common Stock (TPST)
Price$1.94
Favorite Metrics
Price vs S&P 500 (26W)-89.66%
Price vs S&P 500 (4W)-23.90%
Market Capitalization$28.11M
All Metrics
Book Value / Share (Quarterly)$1.43
P/TBV (Annual)4.17x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-7.52
Price vs S&P 500 (YTD)-35.85%
Gross Margin (TTM)-46.67%
Net Profit Margin (TTM)-9760.00%
EPS (TTM)$-10.40
10-Day Avg Trading Volume0.43M
EPS Excl Extra (TTM)$-10.40
EPS (Annual)$-19.50
ROI (Annual)-164.22%
Gross Margin (Annual)-166.67%
Cash / Share (Quarterly)$1.69
Revenue Growth QoQ (YoY)0.00%
ROA (Last FY)-100.86%
Revenue Growth TTM (YoY)-6.25%
EBITD / Share (TTM)$-9.75
ROE (5Y Avg)-142.93%
Operating Margin (TTM)-10020.00%
Cash Flow / Share (Annual)$-9.89
P/B Ratio4.43x
P/B Ratio (Quarterly)7.19x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)68.67x
Net Interest Coverage (TTM)-87.30x
ROA (TTM)-125.12%
EPS Incl Extra (Annual)$-19.50
Current Ratio (Annual)2.21x
Quick Ratio (Quarterly)2.23x
3-Month Avg Trading Volume0.16M
52-Week Price Return-72.97%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.08
P/S Ratio (Annual)93.71x
Asset Turnover (Annual)0.00x
52-Week High$12.23
EPS Excl Extra (Annual)$-19.50
CapEx CAGR (5Y)1.69%
Tangible BV CAGR (5Y)-22.38%
26-Week Price Return-80.92%
Quick Ratio (Annual)2.17x
13-Week Price Return-23.14%
Total Debt / Equity (Annual)0.33x
Current Ratio (Quarterly)2.30x
Enterprise Value$20.6
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-35.03%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-16970.00%
Cash / Share (Annual)$8.95
3-Month Return Std Dev103.63%
Net Income / Employee (TTM)$-2
ROE (Last FY)-218.78%
Net Interest Coverage (Annual)-2110.20x
EPS Basic Excl Extra (Annual)$-19.50
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-10.40
ROI (TTM)-253.31%
P/S Ratio (TTM)93.71x
Revenue / Share (Annual)$1.88
Tangible BV / Share (Annual)$1.72
Price vs S&P 500 (52W)-108.06%
Year-to-Date Return-31.71%
5-Day Price Return-8.41%
EPS Normalized (Annual)$-19.50
ROA (5Y Avg)-71.60%
Net Profit Margin (Annual)-16993.33%
Month-to-Date Return19.51%
Cash Flow / Share (TTM)$-2.20
EBITD / Share (Annual)$-19.40
Operating Margin (Annual)-16870.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-106.57%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-10.40
P/B Ratio (Annual)1.90x
Pretax Margin (TTM)-9746.67%
Book Value / Share (Annual)$5.65
Price vs S&P 500 (13W)-26.00%
Beta-1.73x
Revenue / Share (TTM)$1.88
ROE (TTM)-310.89%
52-Week Low$1.50
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.17
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TPSTTempest Therapeutics, Inc. Common Stock | 93.71x | -6.25% | -46.67% | — | $1.94 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Tempest Therapeutics is a late-stage biotechnology company developing small molecule cancer therapeutics designed to directly eliminate tumor cells while activating anti-tumor immunity. The company's clinical-stage pipeline includes TPST-1120 and TPST-1495, targeting distinct mechanisms in oncology.